Statins and Glucose Metabolism: Are All Agents Alike?

Goals

JUPITER Increased Incidence of T2D With Rosuvastatin

Statins and New-Onset T2D: Meta-Analysis of 13 Clinical Trials

T2D Risk: No Difference Between Most Statins

Statins and New-Onset T2D: Meta-Analysis of 13 Clinical Trials

WOSCOPS and LIPID Trials

WOSCOPS

WOSCOPS Reduction in LDL-C

Statins and the Development of Diabetes

Questions Remain

Pitavastatin Does Not Adversely Affect FBG, HbA1c, or T2D Development

Pitavastatin Treatment for Increased ASCVD Risk in HIV Infection

J-PREDICT Primary Outcome: Cumulative Incidence of Diabetes

Risk for New-Onset T2D Stratified by Risk Factors and Statin Dose

Risk Factors

Risk for New-Onset T2D Stratified by Age

Trajectories to Developing T2D

Key Factors for Reduction of CV Events

JUPITER: CV Benefit vs T2D Risk

CV/T2D Risk

T2D and Macrovascular Disease

Pitavastatin Has Neutral Effect on FBG Across the Dose Range

Pitavastatin and Pravastatin: Minimal CYP Involvement

CYP Systems

How Statins Impair Glucose and Insulin Metabolism

LDL-Rs and Genetic Targets

Not Just the HMG-CoA Reductase

Conclusions: Statin-Associated T2D

Multidisciplinary Team Approach: Preventing CVD and T2D

Abbreviations

Abbreviations (cont)

Abbreviations (cont)